Cargando…

Evolution of systemic therapy for advanced HCC patients: Did we make progress in 2022?

Detalles Bibliográficos
Autores principales:	Wong, Jeffrey Sum Lung, Leung, Roland, Cheung, Tan To, Yau, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187857/ https://www.ncbi.nlm.nih.gov/pubmed/37184515 http://dx.doi.org/10.1097/HC9.0000000000000117

Ejemplares similares

Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC
por: Dong, Yawen, et al.
Publicado: (2021)

What did we know? what did we do?: making decisions in large organizations
por: Herzner, Fred, et al.
Publicado: (2018)

Metastatic Pancreatic Cancer: Are We Making Progress in Treatment?
por: Chiu, Joanne, et al.
Publicado: (2012)

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
por: Wong, Jeffrey Sum Lung, et al.
Publicado: (2021)

Yes, we did it!
por: CERN Bulletin
Publicado: (2010)

Decision making in elderly HCC
por: Trovato, M A, et al.
Publicado: (2011)

The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
por: Wong, Jeffrey Sum-Lung, et al.
Publicado: (2021)

The influence of age in decision-making of patients with HCC
por: Puleo, S, et al.
Publicado: (2010)

What else did we learn?
por: Pojer, M
Publicado: (2009)

What did we learn today?
por: Midtvedt, Tore
Publicado: (2015)

Immune System and Hepatocellular Carcinoma (HCC): New Insights into HCC Progression
por: Kotsari, Maria, et al.
Publicado: (2023)

Making Diabetes Care Fit—Are We Making Progress?
por: Ruissen, Merel M., et al.
Publicado: (2021)

Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?
por: Negri, Francesca, et al.
Publicado: (2021)

LEP/SLC : What did we expect ? What did we achieve ? A very quick historical review
por: Treille, D
Publicado: (2001)

Did contain hackers - A brief summary of MCH2022
por: Bachmann, Richard
Publicado: (2022)

Interpol review of toxicology 2019–2022
por: Cheng, Jack Yuk-ki, et al.
Publicado: (2022)

Should we undertake surveillance for HCC in patients with MAFLD?
por: Norero, Blanca, et al.
Publicado: (2023)

What did we learn in school today ?
por: Tröster, D A
Publicado: (1989)

How and what did we do in 1999
por: Despas, C
Publicado: (2000)

Hereford and Cholera — Why Did We Escape It?
por: Ross, John
Publicado: (1990)

Global Blindness: The Progress We Are Making and Still Need to Make
por: Taylor, Hugh R.
Publicado: (2019)

Did We or Didn't We? Louse Genetic Analysis Says Yes
Publicado: (2004)

Did We Get What We Aimed for 10 Years Ago?
por: Augustinus, A, et al.
Publicado: (2011)

We can do much better than what we did
por: Lee, Sang-Hak
Publicado: (2020)

NAFLD-Associated HCC: Progress and Opportunities
por: Geh, Daniel, et al.
Publicado: (2021)

The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC
por: Rusu, Ioana, et al.
Publicado: (2022)

Advances in Immunotherapy for Hepatocellular Carcinoma (HCC)
por: Bicer, Fuat, et al.
Publicado: (2023)

Management of adrenocortical carcinoma: are we making progress?
por: Kiesewetter, Barbara, et al.
Publicado: (2021)

What did the EJGP do well in 2022, and What is the Journal’s plan?
por: Stoffers, Jelle
Publicado: (2023)

Who coined the term “status gelasticus”? We did
por: Ng, Yu-tze
Publicado: (2009)

Sorting the Magnets in the Machine: What did/will We Gain ?
por: Bottura, L
Publicado: (2006)

Treatment of Gliomas: How did we get here?
por: Chowdhary, Michelle M., et al.
Publicado: (2015)

Smoking and COVID-19: Did we overlook representativeness?
por: Wenzl, Thomas
Publicado: (2020)

Chest wall injury centers—how we did it
por: Forrester, Joseph D., et al.
Publicado: (2021)

Liposomes in Cancer Therapy: How Did We Start and Where Are We Now
por: Fulton, Melody D., et al.
Publicado: (2023)

Muscle fatigue and muscle weakness: what we know and what we wish we did
por: Karatzaferi, Christina, et al.
Publicado: (2013)

You did what?!: the biggest blunders professionals make
por: Zoller, Kim, et al.
Publicado: (2015)

Protocol to track the biosynthesis of cholesterol in cultured HCC cells using (13)C compound-specific stable isotopic tracers
por: Cybulski, Jonathan D., et al.
Publicado: (2023)

Did you say career evolution at CERN?
por: Association du personnel
Publicado: (2009)

Did you say career evolution? (continued)
por: Association du personnel
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ljc1q72l0fkdel338i73n4nkfi